Triveni Bio Stock
HealthTechLooking to sell Triveni Bio stock or options?
Triveni Bio has developed a drug discovery platform focused on creating targeted therapies for immune and inflammatory (I&I) disorders. Utilizing a genetics-informed methodology, the company identifies patients who are most likely to benefit from their treatments, enhancing precision and minimizing trial and error. This approach helps in advancing the development of novel therapies that are more effective and less toxic than existing options, ultimately providing patients with improved treatment outcomes.
Deep Track Capital, Polaris Partners, Goldman Sachs Asset Management, Borealis Ventures, Fidelity Management & Research, Magnetic Ventures, OrbiMed, Cormorant Asset Management, Viking Global Investors, The Invus Group, Atlas Venture, Alexandria Venture Investments.
Our available services for this company
Management Team
Board Members
Triveni Bio’s stock FAQs
Triveni Bio is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Triveni Bio stock. Depending on Triveni Bio’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Triveni Bio stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Triveni Bio stock in two ways. First, Triveni Bio employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Triveni Bio stock. Note that all transactions in Triveni Bio shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Triveni Bio stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Triveni Bio stock. Typically, shares of private companies like Triveni Bio are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Oct 2024, Triveni Bio is reported to have closed an equity financing in which the investors valued the company at $310M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Triveni Bio shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Triveni Bio is not currently publicly traded, it does not have a ticker symbol.
Triveni Bio has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Triveni Bio is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Triveni Bio shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
Other HealthTech Companies in Collective's mid-stage Target Portfolio.
